PDAB Considerations and Potential Market Access Impacts

ADVI experts Allison Schneider and Yana Volman discuss Prescription Drug Affordability Boards (PDABs), which function to identify what are consider high cost drugs and recommend policy solutions related to drug pricing issues. Hear more about PDAB eligibility criteria, how PDABs influence market access, and more.

Pharmaceutical manufacturers should realize that upper payment limits or ups, despite their best intentions, can have really extensive unintended consequences for patient access and patient affordability.



Solution Leader, Market Access – Biopharma

Yana leads strategic consulting efforts for access-related issues and develops effective communication campaigns designed to ensure appropriate drug management and patient access.


Senior Manager

Allison is responsible for monitoring issues in the pharmaceutical space, assisting clients with a range of issues including health reform legislation and subsequent federal and state implementation; Medicaid, Medicare Advantage, and Medicare Parts B and D policy and payment; Inflation Reduction Act implications; commercial payer delivery and payment reform issues, and state healthcare policies.

Full Transcript

We look forward to discussing how these issues are relevant to your business needs. Our team is working at the intersection of policy data, insights, and market access engagement. We are here to help track and monitor ongoing developments and also help you develop solutions unique to your business situation. Learn more and get in touch today.

Interested in getting in touch with Yana?

Yana Volman

Solution Leader, Market Access Biopharma